Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

10.1245/s10434-007-9356-1
Annals of Surgical Oncology 14:2477-2484 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Black, D.
Right arrow Articles by Smith, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Black, D.
Right arrow Articles by Smith, B.

Original Article

Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy

Dalliah Black, MD1, Michelle Specht, MD1, Janie M. Lee, MD2, Francisco Dominguez, MD1, Michele Gadd, MD1, Kevin Hughes, MD1, Elizabeth Rafferty, MD2 and Barbara Smith, MD, PhD1

1 Department of Surgical Oncology, Massachusetts General Hospital, Yawkey Building, 7th Floor, 55 Fruit Street, Boston, Massachusetts 02114, USA
2 Department of Breast Imaging, Massachusetts General Hospital, Yawkey Building, 7th Floor, 55 Fruit Street, Boston, Massachusetts 02114, USA

Correspondence: Address correspondence and reprint requests to: Michelle Specht, MD; E-mail: mspecht{at}partners.org

Background: High-risk patients undergoing prophylactic mastectomy (PM) may have unsuspected cancers identified on pathology. The optimum way to identify and manage them is controversial. Magnetic resonance imaging (MRI) may identify occult cancer preoperatively. Sentinel lymph node biopsy (SLNB) allows intraoperative staging and axillary dissection during the same operation. We determined the efficacy and cost of MRI and/or SLNB in managing high-risk PM patients.

Methods: We reviewed 192 PMs in 173 patients from 1999 to 2005. Costs were estimated for MRI and SLNB during PM by the 2005 Medicare Resource-Based Relative Value Scale. We also estimated costs and procedures for the four strategies in a larger hypothetical cohort.

Results: A total of 19 (10%) of 192 PMs contained occult cancers, 14 ductal carcinoma-in-situ (DCIS) and 5 invasive ductal carcinoma (IDC). In 59 patients, MRI detected an IDC but missed two DCIS and an IDC. Positive MRIs generated an additional average cost of $1207 per patient. In 56 PMs with SLNB, 6 occult cancers were found, 5 DCIS and 1 IDC, all with negative SLNBs. Adding a SLNB costs an additional average of $644. A theoretical analysis demonstrated that PM alone costs $808 per patient, PM with SLNB costs $1420, PM with MRI and selective SLNB costs $1774, and PM with routine MRI and SLNB costs $2379.

Conclusions: MRI adds great cost and misses most occult cancers in PMs. SLNB allows the rare patient with occult IDC to avoid axillary dissection but adds cost. Given the low rate of unsuspected invasive cancers and the costs of MRI and SLNB, neither is recommended as standard practice for PM patients.

Key Words: Prophylactic mastectomy • Breast MRI • Sentinel lymph node biopsy • Occult cancer • Cost analysis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.